Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Katrine Prætorius; Daniel P Henriksen; Johannes M Schmid; Pernille Printzlau; Lars Pedersen; Hanne Madsen; Ehm A Andersson; Louise Klokker Madsen; Bo L Chawes

doi:10.1183/23120541.00306-2021

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Katrine Prætorius, Daniel P Henriksen, Johannes M Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A Andersson, Louise Klokker Madsen, Bo L Chawes

10 Citationer (Scopus)

Abstract

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9.

Originalsprog	Engelsk
Artikelnummer	00306-2021
Tidsskrift	ERJ Open Research
Vol/bind	7
Udgave nummer	3
ISSN	2312-0541
DOI	https://doi.org/10.1183/23120541.00306-2021
Status	Udgivet - aug. 2021

Adgang til dokumentet

10.1183/23120541.00306-2021

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{71e08ef376aa417f8d565501f448c6f8,

title = "Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma",

abstract = "This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9.",

author = "Katrine Pr{\ae}torius and Henriksen, \{Daniel P\} and Schmid, \{Johannes M\} and Pernille Printzlau and Lars Pedersen and Hanne Madsen and Andersson, \{Ehm A\} and Madsen, \{Louise Klokker\} and Chawes, \{Bo L\}",

note = "Copyright {\textcopyright}The authors 2021.",

year = "2021",

month = aug,

doi = "10.1183/23120541.00306-2021",

language = "English",

volume = "7",

journal = "ERJ Open Research",

issn = "2312-0541",

publisher = "BMJ Publishing Group Ltd",

number = "3",

}

TY - JOUR

T1 - Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

AU - Prætorius, Katrine

AU - Henriksen, Daniel P

AU - Schmid, Johannes M

AU - Printzlau, Pernille

AU - Pedersen, Lars

AU - Madsen, Hanne

AU - Andersson, Ehm A

AU - Madsen, Louise Klokker

AU - Chawes, Bo L

PY - 2021/8

Y1 - 2021/8

N2 - This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9.

AB - This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9.

UR - https://www.scopus.com/pages/publications/85116849605

U2 - 10.1183/23120541.00306-2021

DO - 10.1183/23120541.00306-2021

M3 - Journal article

C2 - 34476242

SN - 2312-0541

VL - 7

JO - ERJ Open Research

JF - ERJ Open Research

IS - 3

M1 - 00306-2021

ER -

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater